Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Cetuximab + Afatinib for Head and Neck Cancer
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing a combination of cetuximab and afatinib for patients with squamous cell carcinoma of the head and neck who have previously been treated with a platinum-based regimen or an immune checkpoint inhibitor.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service